Recently, he serves as a director of Taiwan Society of immunotherapy for Cancer (TSITC). The goal is to promote the safety and efficacy of novel immunotherapy to cure patients with cancer.
Dr. Chang stands in the front line in this field, as a recognized physician, he firstly introduced sentinel lymph node detection in patients with breast cancer, hosted global clinical trials several times, and advocated genetic testing for molecular-targeted therapy. Up to date, he has published more than 100 research papers.